Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Infliximab is a prescription tumor necrosis factor blocker given by intravenous infusion. Current generic labeling includes Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Pediatric Crohn disease and ulcerative colitis indications begin at age 6.
read more about infliximab ...Infliximab binds to soluble and transmembrane forms of tumor necrosis factor alpha and inhibits their interaction with TNF receptors. This reduces inflammatory signaling involved in several immune-mediated diseases.
Infliximab is used in adults with Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or chronic severe plaque psoriasis under indication-specific criteria. It is also used for moderately to severely active Crohn disease and ulcerative colitis in pediatric patients age 6 and older.
Crohn disease and ulcerative colitis use 5 mg per kg intravenously at weeks 0, 2, and 6, then every 8 weeks. Rheumatoid arthritis uses 3 mg per kg on the same induction schedule and then every 8 weeks with methotrexate. Ankylosing spondylitis uses 5 mg per kg at weeks 0, 2, and 6, then every 6 weeks, while psoriatic arthritis and plaque psoriasis use 5 mg per kg every 8 weeks after induction.
Infliximab carries boxed warnings for serious infections and malignancies. Risks include tuberculosis, bacterial sepsis, invasive fungal infections, lymphoma, and other cancers. Other serious concerns include hepatitis B reactivation, liver injury, worsening heart failure, neurologic reactions, blood-cell abnormalities, and serious infusion reactions.
Current labeling includes Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
The labeled regimen uses 5 mg per kg intravenously at weeks 0, 2, and 6.
Yes. Current labeling includes Crohn disease and ulcerative colitis in patients age 6 and older.
Yes. The boxed warnings concern serious infections and malignancies.
Infliximab. https://www.ncbi.nlm.nih.gov/books/NBK500021/. Date Accessed October 5, 2026.
Infliximab Injection: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a604023.html. Date Accessed October 5, 2026.
Infliximab (Chimeric Anti-Tumour Necrosis Factor Alpha Monoclonal Antibody) Versus Placebo in Rheumatoid Arthritis Patients Receiving Concomitant Methotrexate: A Randomised Phase III Trial. https://pubmed.ncbi.nlm.nih.gov/10622295/. Date Accessed October 5, 2026.
Maintenance Infliximab for Crohn's Disease: The ACCENT I Randomised Trial. https://pubmed.ncbi.nlm.nih.gov/12047962/. Date Accessed October 5, 2026.
REMICADE (Infliximab) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a0a046c1-056d-45a9-bfd9-13b47c24f257. Date Accessed October 5, 2026.